1083182-45-9

Upstream product

• 937273-33-1 3-allyloxymethyl-4-(2-pyrrolidin-1-yl-ethoxy)phenylamine 
• 1083182-37-9 2-chloro-4-(2-fluoropyridin-4-yl)-5-methylpyrimidine 
• 1780-31-0 2,6-dichloro-5-methylpyrimidine 
• 937273-30-8 [2-(2-chloroethoxy)-5-nitrophenyl]methanol 
• 937273-31-9 1-(2-chloroethoxy)-2-((allyloxy)methyl)-4-nitrobenzene 
• 937273-32-0 1-(2-{4-nitro-2-[(prop-2-en-1-yloxy)methyl]phenoxy}ethyl)pyrrolidine 
• 401815-98-3 2-fluoropyridin-4-ylboronic acid 
• 97-51-8 5-Nitrosalicylaldehyde 
• 110837-53-1 2-(2-chloroethoxy)-5-nitrobenzaldehyde 

Downstream Products

• 1083182-47-1 [3-allyloxymethyl-4-(2-pyrrolidin-1-ylethoxy)phenyl]-[4-(2-but-3-enyloxypyridin-4-yl)-5-methylpyrimidin-2-yl]amine 

Relevant academic research and scientific papers

Discovery of the macrocycle (9 E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25- trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9, 14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of Janus kinase 2/Fms-liketyrosine kinase-3 (J

Herein, we describe the synthesis and SAR of a series of small molecule macrocycles that selectively inhibit JAK2 kinase within the JAK family and FLT3 kinase. Following a multiparameter optimization of a key aryl ring of the previously described SB1518 (

PYRIDYL SUBSTITUTED PYRIMIDINE DERIVATIVES

The present invention relates to pyridyl substituted pyrimidine compounds that are useful as agents for the treatment of kinase related disorders such as proliferative disorders. More particularly, the present invention relates to oxygen linked and pyridy